NovaBay Pharmaceuticals Reports Record Amazon Prime Day Sales

NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) reports record sales of Avenova®-branded eyecare products during the Amazon Prime Day event, which was held July 16-17, 2024. Over the two-day period, Avenova sales were 17% higher compared with Prime Day 2023 and were up 40% over Prime Day 2022.

“We reached another new sales record during the 2024 Amazon Prime Day event as consumers took advantage of discounts on our high-quality Avenova products,” said Justin Hall, NovaBay CEO. “This event offered great pricing to our repeat customers on the Avenova products they’ve come to rely on, as well as to those new to our brand and our best-in-class dry eye product portfolio."

“In recent years the prevalence of dry eye disease has been rising while we’ve gained a better understanding of its multifactorial nature. In response, NovaBay offers a full portfolio of scientifically developed products for each step of the standard at-home dry eye treatment regimen,” he added. “Our mission is for Avenova to become a one-stop destination for the 25 million Americans who suffer from dry eye.”

NovaBay’s flagship product, Avenova Lid & Lash Solution, is designed to remove foreign material including microorganisms and debris from the skin around the eye as well as the eyelid. The Avenova product family also includes Avenova Lubricating Eye Drops for instant relief, Avenova Warm Eye Compress to soothe the eyes and the i-Chek by Avenova to monitor physical eyelid health. NovaBay also offers Avenova product bundles specifically designed to provide easy, affordable and effective solutions for individualized needs.

About NovaBay Pharmaceuticals, Inc.

NovaBay's leading product Avenova® Lid & Lash Solution is often recommended by eyecare professionals for blepharitis and dry eye disease. Manufactured in the U.S., Avenova spray is formulated with NovaBay's patented, proprietary, stable and pure form of hypochlorous acid. All Avenova products are available directly to consumers through online distribution channels such as Amazon.com and Avenova.com.

Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including, but not limited to, statements that are based upon management's current expectations, assumptions, estimates, projections and beliefs. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results or achievements to be materially different and adverse from those expressed in or implied by the forward-looking statements. Factors that might cause or contribute to such differences include, but are not limited to, risks and uncertainties relating to difficulties or delays in manufacturing, distributing, and selling the Company's products. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. Other risks relating to the Company's business, including risks that could cause results to differ materially from those projected in the forward-looking statements in this press release, are detailed in the Company's latest Form 10-Q/K filings with the SEC, as may be amended from time to time, especially under the heading "Risk Factors." The forward-looking statements in this release speak only as of this date, and the Company disclaims any intent or obligation to revise or update publicly any forward-looking statement except as required by law.

Socialize and Stay Informed on NovaBay’s Progress Like us on Facebook Follow us on X Connect with NovaBay on LinkedIn Visit NovaBay's Website

Avenova Purchasing Information For NovaBay Avenova purchasing information: Please call 800-890-0329 or email sales@avenova.com Avenova.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20240730296981/en/

NovaBay Contact Justin Hall Chief Executive Officer and General Counsel 510-899-8800 jhall@novabay.com Investor Relations Contact LHA Investor Relations Jody Cain 310-691-7100 jcain@lhai.com

NovaBay Pharmaceuticals (AMEX:NBY)
過去株価チャート
から 6 2024 まで 7 2024